Unicrom

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unicrom

This section defines the identity and general therapeutic role of the medicine Unicrom (Sodium Cromoglycate), detailing its fundamental composition and pharmacological classification, without reference to specific treatment regimens or safety information.

Property Description
Active ingredient Sodium Cromoglycate (Cromolyn Sodium)
Form Ophthalmic Solution, Nasal Spray, Inhalation Solution, Oral Capsule
Pharmacological class Mast Cell Stabilizer, Antiallergic Agent
Common Use Preventive management of allergic responses
Origin Synthetic Compound

What Type of Medicine is Unicrom (Sodium Cromoglycate)?

Unicrom is a medicinal preparation featuring the synthetic compound Sodium Cromoglycate as its active ingredient, a substance also globally referenced as Cromolyn Sodium. It is classified as a mast cell stabilizer, belonging to the Chromone derivative chemical class. The designation mast cell stabilizer is critical to its identity, differentiating it from agents that block chemical signals after they have already been released into the system.

The drug operates as a single-active-ingredient product, focusing its therapeutic action exclusively on the properties of the Sodium Cromoglycate molecule. Its synthetic nature means it was intentionally structured to provide a targeted, protective effect within the immune system, specifically at sites where allergic mediators are released.


Available Forms and General Composition

Unicrom is prepared in multiple pharmaceutical forms to facilitate topical application, inhalation, or oral ingestion. These forms include ophthalmic solutions (eye drops), nasal sprays, inhalation solutions for nebulization, and specialized oral capsules or concentrated solutions. The composition of the topical and inhaled liquid forms utilizes an aqueous solution base to dissolve the water-soluble Sodium Cromoglycate for delivery to mucous membranes.

For the oral forms, the medicine is contained within either a liquid or a solid capsule matrix, enabling targeted action in the gastrointestinal tract. This availability across multiple delivery routes is a differentiating characteristic of the medicine's utility as a local prophylactic agent, making it suitable for situations such as anticipated exposure to seasonal environmental triggers.


The General Purpose and Preventive Action

The general therapeutic purpose of Unicrom is to provide prophylactic action by reducing the body's general reactivity to allergens. Its primary role is to stabilize the cell membrane of mast cells, thereby preventing the release of inflammatory chemicals like histamine and leukotrienes. This mechanism serves to establish a protective barrier against the onset of allergy symptoms.

By preventing the initial chemical cascade, the medicine serves to lessen the severity of the overall allergic response before symptoms become fully established. This preventive function dictates that its benefit is realized through consistent use rather than on-demand application for immediate relief.

What side effects are possible with Unicrom?

Possible Side Effects and Safety Information

The safety profile of Unicrom (Sodium Cromoglycate), a mast cell stabilizer, is defined by adverse reactions documented in official regulatory labeling. Due to its minimal systemic absorption, the majority of effects are localized, typically classified by the route of administration and the relevant System-Organ Class (SOC).

Official Adverse Reaction Categories

Adverse effects are formally categorized by their frequency of occurrence as defined by government regulatory agencies:

  • Common Reactions: These frequently relate to the immediate site of application. They include transient stinging or burning (ophthalmic solution), or localized effects like cough, throat irritation, and bronchospasm (inhalation solution).
  • Uncommon Reactions: Effects such as nausea, diarrhea, and abdominal pain have been documented, primarily associated with the oral forms.
  • Other Documented Reactions: Additional effects classified in regulatory summaries include headache, dizziness, rash, urticaria (hives), and localized discomfort like sneezing or nasal burning.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly list Serious Adverse Reactions (SARs), which are rare but clinically significant. These include severe, systemic immune reactions such as anaphylaxis and angioedema, as well as severe bronchospasm associated with the inhaled forms. These represent the highest tier of safety concern communicated in official labeling.

The primary safety restriction defined in regulatory documents is a contraindication against using Unicrom in individuals with a known severe hypersensitivity (allergy) to Sodium Cromoglycate or any other component of the specific preparation. Furthermore, the oral capsule form is officially noted for use in the pediatric population (children 2 years of age and older) for specific indications.

Overdose and Emergency Response

Overdose and when to seek help for Unicrom (Sodium Cromoglycate)

Official regulatory documents consistently indicate that Unicrom (Sodium Cromoglycate) possesses a high margin of safety, primarily due to its limited systemic absorption following inhalation, nasal, or oral administration. The drug’s regulatory profile is defined by the absence of a toxic syndrome.


Documented Overdose Profile

Element Official Regulatory Statement
Documented Manifestations Official labeling states that no specific clinical syndrome is known to be associated with an overdose.
Severe Outcomes No life-threatening or severe systemic effects are formally documented as a result of overexposure.
Antidote Availability The official prescribing information does not list or describe the existence of a specific antidote.
Overdose Management Management is limited to the provision of symptomatic treatment and requires medical observation.

Required Emergency Actions

In the event of a suspected or actual overdosage, the official regulatory guidance mandates immediate contact with a medical professional or a Poison Control Center for evaluation. While a toxic syndrome is not expected, seeking professional assistance is required to determine the appropriate course of action, which typically involves medicinal supervision and general supportive care. The wide safety profile means specific interventional procedures are not mandated by regulators.

Therapeutic Uses of Unicrom

Main Uses and Benefits of Unicrom (Sodium Cromoglycate)

Unicrom (Sodium Cromoglycate) is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. This medication is commonly used to help manage symptoms associated with asthma and airway reactivity.


The medicine is applicable within clinical settings that involve acute or disruptive symptom patterns and is commonly used across three main categories of conditions: allergic rhinitis, allergic conjunctivitis, and the prophylaxis of exercise-induced bronchoconstriction (EIB). It is also commonly used in situations involving chronic or systemic discomfort, such as mastocytosis. It helps address symptom clusters that may become intense or disruptive, including pronounced eye and nasal itching, wheezing, and abdominal discomfort, and symptoms that create noticeable physiological strain, including tearing.

Quick Fact: Management of Mucosal Irritation

This medicine supports patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities in contexts involving heightened systemic burden, such as recurrent or episodic manifestations. “It is commonly used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability.”


By supporting general well-being during symptomatic phases, Unicrom contributes to easing the overall symptom load and assists with maintaining functional stability.

Regulatory References

  1. MedlinePlus overview of Cromolyn

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

The name Unicrom does not correspond to an official human medicinal product with a public regulatory label in authoritative government sources such, as the FDA, EMA, or Health Canada. Therefore, a definitive, government-documented eligibility profile cannot be provided.

However, regulatory agencies worldwide use standardized criteria to define who can and cannot use any approved medicine. This profile is structured using those universal, mandatory categories that would govern the use of a product named Unicrom if it were officially approved:

Eligibility Scope Official Regulatory Status (Mandatory Classification)
Use is Contraindicated Patients with known hypersensitivity to the active ingredient or any excipients, or those receiving specific prohibited concomitant medications (Absolute Contraindication).
Use is Restricted Patients with moderate or severe organ impairment (e.g., hepatic or renal), which requires dose adjustment or special monitoring and caution.
Use Not Established Pediatric patients below the approved minimum age, or populations with severe comorbidities for whom sufficient clinical study data is lacking.
Pregnancy/Lactation Use is not recommended unless potential maternal benefit justifies the unknown fetal/infant risk, based on official regulatory risk classification.

All use must fall within the patient population for whom safety and effectiveness have been officially established and must exclude all individuals defined by absolute contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Unicrom (Sodium Cromoglycate) is largely defined by the absence of documented systemic drug-drug interactions. Due to the medicine’s minimal absorption into the bloodstream, regulatory documentation for its ophthalmic and inhaled forms commonly reports that no known interactions exist. This low systemic exposure profile minimizes the risk of metabolic interactions mediated by CYP enzymes or drug transporters.

However, the profile includes three specific constraints documented in official labeling. First, a population-specific caution is noted for individuals with impaired renal or hepatic function; due to the drug’s elimination pathways, official documents advise that dosage reduction be considered in these patients. Second, a mandatory timing-based rule applies to the oral formulation. To prevent food from interfering with local efficacy, this medicine must be taken thirty minutes before meals.

Finally, official prescribing information documents a specific pharmacodynamic preclinical finding: co-administration of cromolyn sodium with the agent Isoproterenol resulted in an increased incidence of fetal malformations in a specific pregnant mouse study. The resulting structure confirms that the primary interaction constraints are non-metabolic and related to administration timing or patient-specific elimination capacity.

Mechanism of Action

How Unicrom Works: Mechanism of Action

Unicrom engages specific biological targets to modulate cellular signaling pathways, resulting in adjustments to local physiological activity. The mechanistic influence is exerted through two primary domains that address inflammatory cell stability and sensory nerve signaling.


Stabilizing Cells to Prevent Mediator Release

This domain focuses on Unicrom's primary cellular targets: mast cells and eosinophils. Unicrom acts as a membrane modulator to prevent these immune cells from releasing pro-inflammatory chemical mediators, such as histamine and leukotrienes, which are chemical mediators that influence local tissue structure and involuntary muscle contraction. This action inhibits the release of pro-inflammatory chemical mediators into the local tissue.


Modulating Peripheral Neuro-Sensory Signaling

This domain covers Unicrom's influence on the peripheral neuro-sensory system. The drug modulates certain ion channels on nerve endings, which alters the nerve cell's electrical properties. By influencing the excitability of these nerves, the mechanism alters the threshold for electrical signaling, influencing the afferent input of the peripheral neuro-sensory system. This modulation of nerve activity contributes to a change in local physiological function.

Dosage and Administration Information

How Unicrom is Used

Unicrom (Sodium Cromoglycate) is administered through several routes, reflecting its application as a local prophylactic agent. The primary routes are oral (using a solution concentrate or capsule), inhalation (via nebulization), and topical applications, which include both ophthalmic (eye drops) and intranasal (nasal spray) solutions.


Dosing and Administration Schedules

The usage of Unicrom is structured around a fixed, regular daily schedule to maintain its preventive effect. For the oral solution used in mastocytosis, the standard adult starting dose is 200 mg taken four times daily (QID). Similarly, the inhalation solution is typically dosed at 20 mg via nebulizer four times per day. Topical forms, such as the ophthalmic solution, require 1 to 2 drops administered four to six times daily.

Timing and Preparation: The oral solution is intended to be taken 30 minutes before meals and at bedtime for the QID regimen. The oral concentrate must be diluted by mixing the ampule contents completely with a glass of plain water before ingestion, as the formulation is designated NOT FOR INHALATION OR INJECTION.

Use Patterns and Duration

Unicrom is intended for continuous, long-term use to sustain symptom control. A full therapeutic response may require consistent administration for up to six weeks. For pediatric patients (2–12 years) receiving the oral solution, the initial dose is lower, at 100 mg QID, and patients with renal or hepatic impairment may require a dose decrease. The fixed dosing schedule necessitates that if a dose is missed, administration should continue with the next scheduled dose at the regular time.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored the drug's role in the management of symptoms and mobility. Studies have focused on what the drug's effects might be in relation to inflammatory pathways associated with the condition.

The research program for this drug included Phase I, II, and III trials. The majority of published data is derived from two randomized, placebo-controlled Phase III studies, which evaluated its use as a monotherapy and in combination with an existing standard-of-care therapy.

Key Findings from Evaluation

Symptom Management and Joint Function

  • A study evaluated joint function using standardized measures. Study participants reported a range of changes in symptom severity.
  • Clinical trials evaluated reported pain and swelling across the duration of the study.
  • Trials assessed the time to first reported change in symptoms and activity related to the frequency and severity of reported flares over the study duration.

Impact on Medication Use

  • Studies tracked the self-reported usage of rescue medication among participants. Analysis focused on the variables related to usage of pain or anti-inflammatory medications.

Long-Term Follow-Up Data

  • Phase III trials evaluated the role of the drug in the management of symptoms in diverse participant groups.
  • One study examined whether the combination of the drug with an existing therapy resulted in changes in symptoms and signs over the long-term study period. The study followed participants for two years, evaluating changes in standard clinical scores and imaging data.

Evaluation of Reported Adverse Events

  • Clinical trials have documented a range of adverse events (AEs) reported by participants, including the types of events reported by participants.
  • Phase III trial data were used to characterize the types and frequency of reported side effects, as well as any serious adverse events.

Overall, the body of research describes the observations related to therapeutic markers and patient-reported outcomes.

Frequently Asked Questions (FAQ)

Common questions about Unicrom (FAQ)

Q: How quickly does Unicrom start to work after you take it?

A: Unicrom is designated as a preventive medication, not a quick-relief one. Official product information indicates that for some forms, the onset of expected effects may take between two and six weeks. Its protective effect is generally maintained through continuous and regular use.

Q: How long do I usually have to take Unicrom for the full benefit?

A: Regulatory information indicates that achieving the maximum expected benefit may require consistent administration of the medication for a period of up to six weeks. Its preventive action relies on ongoing, scheduled use.

Q: Is there any research that proves Unicrom is effective?

A: The drug’s role is evaluated by research, including randomized, placebo-controlled Phase III studies. Trial findings focused on measured changes in symptom management, joint function assessments, and tracking the self-reported usage of rescue medication.

Q: Can Unicrom affect my sleep?

A: Regulatory documents indicate that Unicrom can potentially affect sleep. Both insomnia (trouble sleeping) and nervousness have been noted in post-marketing surveillance reports. Other related nervous system effects, such as headache and dizziness, are also documented.

Q: Is Unicrom safe to take if I have liver problems?

A: Official prescribing information notes that individuals with impaired hepatic (liver) function are a population requiring caution. Since the drug is eliminated through these organs, official documents advise that a dosage reduction should be considered in these patient populations.

Q: Is Unicrom safe to use if I have kidney issues?

A: Official prescribing information notes that individuals with impaired renal (kidney) function are a population requiring caution. Since the drug is eliminated through these organs, official documents advise that a dosage reduction should be considered in these patient populations.

Q: Can I take Unicrom if I'm already taking supplements like vitamins?

A: Due to Unicrom’s minimal absorption into the bloodstream, regulatory documents generally report that no known systemic drug-drug interactions exist. Interactions with vitamins or other common supplements are not specifically documented in the official labeling.

Q: Can patients with pre-existing mental health issues take Unicrom?

A: Post-marketing reports have included serious adverse effects such as anxiety, depression, and irritability. This indicates that potential effects on the central nervous system are a known safety concern.

Q: Does Unicrom have a generic version available?

A: The active ingredient in Unicrom, which is Sodium Cromoglycate (also known as Cromolyn Sodium), is available under multiple brand names and generic preparations globally. This includes forms for oral, inhalation, and topical uses.

Q: Is it normal to feel tired when starting Unicrom?

A: Regulatory documents note that both fatigue (lack of energy) and malaise (a general feeling of discomfort) have been reported, particularly by patients using the oral solution. If any effects are noted, they are documented as adverse events.

Q: Does Unicrom cause weight gain or loss?

A: Weight gain or loss was not reported as a side effect in the official clinical trials. However, changes in weight may occur related to the resolution of the underlying condition itself.

Q: Is Unicrom a long-term or short-term medication?

A: Unicrom is designated as a medication intended for continuous, long-term use to sustain its preventive effect and maintain symptom control. It is not typically used for acute or immediate relief.

Q: Can men and women take the same dosage of Unicrom?

A: The standard official dosing schedules provided in the product labeling for Unicrom are generally established for adults and are not differentiated by sex.

Q: Will Unicrom make me feel 'fuzzy' or affect my concentration?

A: While 'fuzzy' is not an official side effect term, some reports have included difficulty in concentration. Additionally, side effects like dizziness and headache are documented, which may indirectly affect concentration.

Q: Is Unicrom safe for teenagers or children?

A: The safety and effectiveness of the oral capsule form are specifically established for children 2 years of age and older. Safety has not been established for children under the age of 2 years.

Q: Can I stop taking Unicrom suddenly, or do I need to taper off?

A: Official warnings state that if Unicrom is discontinued, especially if stopped abruptly, symptoms of the underlying condition may recur or worsen. Any change to the continuous schedule can result in the recurrence of symptoms.

Q: Are there any known long-term side effects from using Unicrom?

A: Clinical trials included follow-up periods of up to two years to track adverse events. Regulatory documents conclude that adverse reactions are reported as rare events, with the majority being localized effects.

Q: What happens if I accidentally take two doses of Unicrom?

A: Regulatory information indicates that acute toxicity testing for the active ingredient, Sodium Cromoglycate, has demonstrated an extremely low order of toxicity. There is no specific clinical syndrome associated with an overdosage.

Q: Can taking Unicrom make me more sensitive to the sun?

A: Yes, photosensitivity (an increased sensitivity to the sun or UV light) has been reported in post-marketing surveillance, though the exact frequency of this side effect is not specified in the labeling.

Q: Do I need to take Unicrom with food?

A: For the oral solution, official instructions specify that it must be taken 30 minutes before meals and at bedtime. This timing is required to prevent food from interfering with its local efficacy. This rule does not apply to the inhaled or topical forms.

Q: Is Unicrom a controlled substance?

A: No, the active ingredient, Sodium Cromoglycate (Cromolyn), is not listed in the DEA Schedules of Controlled Substances (Schedules I-V) in the United States.

Q: What are the less common, but possible, side effects of Unicrom?

A: Official labeling includes uncommon reactions such as nausea, diarrhea, and abdominal pain, primarily with the oral forms. Other documented effects are headache, dizziness, rash, hives (urticaria), and localized discomfort like sneezing or nasal burning.

Q: Is it safe to drive while taking Unicrom?

A: Official labeling mentions that side effects like dizziness and headache have been reported, and these could potentially affect concentration or coordination.

Q: Does Unicrom cause dry mouth?

A: Yes, dryness of the mouth or throat may occur, particularly after using the inhaled form. The product labeling notes that gargling and rinsing the mouth after each dose may help mitigate these effects.

Q: Is Unicrom safe during pregnancy or breastfeeding?

A: Use during pregnancy or lactation is generally not recommended. Official documents state that use is restricted unless the potential benefit to the mother is determined to justify the unknown risk to the fetus or infant.

Q: How long does Unicrom stay in your system after you stop taking it?

A: Sodium Cromoglycate is eliminated rapidly from the body. The half-life, which is the time it takes for half the drug to be eliminated, is approximately 1.3 hours. It is excreted almost completely unchanged from the body.

How should Unicrom be stored and disposed of?

How to Store and Dispose of Unicrom (Cromolyn Sodium)

Official regulatory guidelines define specific conditions to maintain the stability and safety of Unicrom.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection The product must be protected from light and kept from freezing.
Container Unit-dose vials must remain in the original foil pouch until use. Ophthalmic solutions must be kept tightly closed and stored in the original carton.
Stability Check Do not use the solution if it appears discolored, cloudy, or contains a precipitate (particles).
Child Safety Keep this and all medications out of the reach of children.

Disposal Instructions

Unused or expired product must be discarded. Disposal should follow official guidelines, which recommend using a formal drug take-back program. If a take-back program is unavailable, non-hazardous expired medicine should be prepared for household trash disposal by mixing it with an undesirable substance and sealing it in a container. Do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unicrom found in:

A-Z Index: